**Bio-Me AS** 


Gaustadalléen 21 N-0349 Oslo Norway




# Positioning Microbiome Analysis for Precision Medicine

Morten L. Isaksen PhD Founder & CEO Bio-Me


# Precision Medicine – key to more effective treatments





Contribution of microbiome analysis to Precision Medicine


- Many drugs are metabolized by the gut bacteria
  - Digoxin (Chronic heart failure)
  - Metformin (T2DM)
  - Statins (CVD)
  - Immune Check-point inhibitors responders/non-responders
- Increasing number of known drugmicrobiome interactions
- Microbiome amenable to modifications
  - Dietary interventions
  - Probiotics
  - Prebiotics
  - Specific drugs (over 700 clinical trails)




## Microbiome Analysis in Precision Medicine



#### Value-driver #1 – Precision Microbiome Profiling (PMP)



# Value-driver #2 – Exclusive access to world-leading Biobank (HUNT)



Value-driver # 3 – Functional Precision Microbiome Profiling - f-PMP




 $\rightarrow$  Identify species & strains

٠

•

www.bio-me.no

 $\rightarrow$  Optimal routine screening



# **Intellectual Properties**

- 2 patents pending
- Thermo Fisher Scientific partnership
- In-house developed bioinformatics database & software tools
- Access to 15,000 20,000 fecal samples from HUNT study (incl. 6000+ health parameters)



## The Gut Team



#### 3 PhDs 3 MSc Serial entrepreneur



Katapult Accelerator Norway Health Tech

#### Experienced Board



Sverre Munck Chairman Oslo Science Park



Jørgen Thorball MD Serial Entrepreneur XO Ventures BioGaia/ViroGates



**Tore Sagstuen** Big Data consultant Arundo Solutions



Luis Paulsen Serial Entrepreneur Finance & Investment Management